ライフサイエンスコーパス: Pfizer

1 nonclassical cannabinoids was synthesized by Pfizer.

2 nal Institute of Health Research (NIHR), and Pfizer.

3 nadian Cancer Society Research Institute and Pfizer.

4 er Immunotherapy, Wyeth Pharmaceuticals, and Pfizer.

5 Foundation, UK Medical Research Council, and Pfizer.

6 o Nordisk, Bayer HealthCare, [corrected] and Pfizer.

7 PRIMARY FUNDING SOURCE: Penn-Pfizer Alliance and American Heart Association.

8 Pfizer and Bausch & Lomb had the most drops per bottle (

9 Pfizer and National Cancer Institute grant to the Childr

10 diary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (proph

11 or off-label uses of gabapentin sponsored by Pfizer and Parke-Davis, and documents were obtained thro

12 which internal documents were available from Pfizer and Parke-Davis; of these trials, 12 were reporte

13 practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (her

14 titute and ECOG-ACRIN Cancer Research Group, Pfizer, and Bayer.

15 National Institutes of Health, BASF, Pfizer, and DSM Nutritional Products.

16 nce Armstrong Foundation, Roche Diagnostics, Pfizer, and Novartis.

17 ith its dam having received PregSure(R) BVD (Pfizer Animal Health) vaccination prior to the birth of

18 British Heart Foundation, Pfizer, AstraZeneca, Schering-Plough, National Institute

19 Washington University-Pfizer Biomedical Collaborative.

20 BMS, Pfizer, Boehringer Ingelheim, Roche Diagnostics.

21 NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foun

22 NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foun

23 search, Canadian Anesthesiologists' Society, Pfizer Canada, Italian Ministry of Heath, Fonds NutsOhra

24 AstraZeneca, Boehringer Ingelheim (Canada), Pfizer (Canada), MSD, Chest, Heart and Stroke Scotland,

25 Canadian Cancer Society Research Institute, Pfizer, Canadian Institutes of Health Research.

26 Results from a retrospective analysis of 32 Pfizer CNS clinical drug candidates are described.

27 the assay in a high-throughput screen of the Pfizer compound collection to identify inhibitors of 5-L

28 The Pfizer compound CP-31398 has been reported to stabilize

29 oside (AICAR) and inhibition by caffeine and Pfizer compound CP-91149, which bind to GP at distinct s

30 The Pfizer compound library was screened against the catalyt

31 tructurally diverse model compounds from the Pfizer drug library, including ingliforib, furosemide an

32 bb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals

33 U.S. Department of Veterans Affairs and the Pfizer Foundation.

34 micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 in

35 edical Center, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

36 smoking cessation drug varenicline (Chantix; Pfizer, Groton, CT), an alpha4beta2-targeted agonist tha

37 Pfizer had the highest yearly cost at $1198 (P < .001),

38 o the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compa

39 Millennium Inc, Pfizer Inc, Multiple Myeloma Research Foundation, and th

40 funded as investigator initiated research by Pfizer Inc, New York, NY, USA.

41 Pfizer Inc, V Foundation for Cancer Research.

42 Novartis Pharmaceuticals and Pfizer Inc.

43 ologically related to gabapentin (Neurontin; Pfizer Inc., New York, NY).

44 ning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses.

45 aboratories Inc.], and latanoprost [Xalatan; Pfizer, Inc., New York, NY]).

46 gand bioassay response-data (BARD) using 155 Pfizer internal BioPrint assays.

47 Pfizer, International Breast Cancer Study Group, and US

48 Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Networ

49 Here, using the Mason-Pfizer monkey retrovirus dUTPase, we study the dUTPase-c

50 nstitutive transport element of simian/Mason-Pfizer monkey retroviruses and the RNA transport element

51 omprised almost entirely of the CTE of Mason-Pfizer monkey virus (CTE RNA) is exported efficiently fr

52 membrane assembly, PPPY L domain) and Mason-Pfizer monkey virus (cytoplasmic assembly, PPPY L domain

53 pp16 proteins of the type D retrovirus Mason-Pfizer monkey virus (M-PMV) are phosphoproteins that are

54 unodeficiency virus type 1 (HIV-1) and Mason-Pfizer monkey virus (M-PMV) but not Moloney murine leuke

55 Mason-Pfizer monkey virus (M-PMV) capsids that have assembled

56 Mason-Pfizer monkey virus (M-PMV) encodes a transmembrane (TM)

57 Mason-Pfizer monkey virus (M-PMV) encodes a transmembrane glyc

58 High Five cells expressing wild-type Mason-Pfizer monkey virus (M-PMV) Gag precursors accumulate as

59 The Mason-Pfizer monkey virus (M-PMV) Gag protein possesses the ab

60 ived protein of the related retrovirus Mason-Pfizer monkey virus (M-PMV) has previously been reported

61 Mason-Pfizer monkey virus (M-PMV) is a prototypical betaretrov

62 The Mason-Pfizer monkey virus (M-PMV) is the prototype of the type

63 a cellular factor regulating HIV-1 and Mason-Pfizer monkey virus (M-PMV) particle release.

64 lycoprotein incorporation into budding Mason-Pfizer monkey virus (M-PMV) particles and abrogate infec

65 tructures and membrane affinity of the Mason-Pfizer monkey virus (M-PMV) wild-type MA with its two bu

66 We sought to determine whether or not Mason-Pfizer monkey virus (M-PMV), a prototype betaretrovirus

67 of the prototypical type D retrovirus, Mason-Pfizer monkey virus (M-PMV), can assemble in a cell-free

68 he assembled Gag lattices of HIV-1 and Mason-Pfizer monkey virus (M-PMV), the C-terminal domain of CA

69 Mason-Pfizer monkey virus (M-PMV), the prototype type D retrov

70 Mason-Pfizer monkey virus (M-PMV), the prototypical type D ret

71 egulatory element (PRE)-containing and Mason-Pfizer monkey virus (MPMV) constitutive transport elemen

72 nv expression vectors that contain the Mason-Pfizer monkey virus (MPMV) constitutive transport elemen

73 ther a Rev response element (RRE) or a Mason-Pfizer monkey virus (MPMV) constitutive transport elemen

74 t the genome of the simpler retrovirus Mason-Pfizer monkey virus (MPMV) contains an element that serv

75 t the 5' long terminal repeat (LTR) of Mason-Pfizer monkey virus (MPMV) facilitates Rev/Rev-responsiv

76 Here, we demonstrate that Mason-Pfizer monkey virus (MPMV) is resistant to inhibition by

77 as a nonlentiviral retrovirus such as Mason-Pfizer monkey virus (MPMV), and vice versa.

78 onstitutive transport element (CTE) of Mason-Pfizer monkey virus (MPMV), or the pre-mRNA processing e

79 ociation of KIF-4 with Gag proteins of Mason-Pfizer monkey virus (MPMV), simian immunodeficiency viru

80 stitutive transport element (CTE) from Mason-Pfizer monkey virus (MPMV).

81 (HIV-1), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus (MPMV)] and discuss structural featu

82 ing and retention signal CTRS found in Mason-Pfizer monkey virus and that FV Gag has the inherent abi

83 llular capsid transport and release of Mason-Pfizer monkey virus are dependent on myristylation of th

84 d release of murine leukemia virus and Mason-Pfizer monkey virus are insensitive to TSG-5'.

85 ag protein shells-immature capsids--of Mason-Pfizer monkey virus assembled in Escherichia coli from t

86 nscriptional enhancer element from the Mason-Pfizer monkey virus can override the silencing and promo

87 the constitutive transport element of Mason-Pfizer monkey virus can substitute for RRE and Rev at le

88 clear export of mRNAs that contain the Mason-Pfizer monkey virus constitutive transport element (CTE)

89 Tap interacts directly with the Mason-Pfizer monkey virus constitutive transport element (CTE)

90 on of cis-acting elements, such as the Mason-Pfizer monkey virus constitutive transport element (CTE)

91 DeltaCAN had no significant affect on Mason-Pfizer monkey virus constitutive transport element (MPMV

92 either Rev/Rev response element or the Mason-Pfizer monkey virus constitutive transport element.

93 The transmembrane protein of Mason-Pfizer monkey virus contains two heptad repeats that are

94 e transport element (CTE) derived from Mason-Pfizer monkey virus for expression of the viral proteins

95 Unlike most retroviruses, the Mason-Pfizer monkey virus Gag polyproteins assemble into immat

96 SRV-2 and Mason-Pfizer monkey virus have highly homologous elements, whi

97 a unique experimental system in which Mason-Pfizer monkey virus immature capsids are removed from th

98 Mason-Pfizer monkey virus immature capsids selected from the c

99 sarcoma virus IN, rather than HIV-1 or Mason-Pfizer monkey virus IN, were substituted into the struct

100 ntly in the distal zinc knuckle of the Mason-Pfizer monkey virus nucleocapsid protein.

101 For example, Mason-Pfizer monkey virus overcomes cellular restrictions by u

102 export of RNA transcripts derived from Mason-Pfizer monkey virus that contain the constitutive transp

103 ses (HIV-1, murine leukemia virus, and Mason-Pfizer monkey virus), two hepadnaviruses (hepatitis B vi

104 different from that seen in HIV-1 and Mason-Pfizer monkey virus, illustrating further structural div

105 In Mason-Pfizer monkey virus, the required RNA sequence element i

106 ates the CA and NC domains, whereas in Mason-Pfizer monkey virus, this region is densely packed, thus

107 was required for efficient release of Mason-Pfizer monkey virus, which buds primarily by using a PPX

108 of unspliced RNA containing either the Mason-Pfizer monkey virus-CTE or the recently discovered Tap-C

109 ase by a distantly related retrovirus, Mason-Pfizer monkey virus.

110 that interacts with the Gag protein of Mason-Pfizer monkey virus.

111 II) in the absence (control) or presence of Pfizer MTP inhibitor CP-10447 (CP).

112 -Provera (depot medroxyprogesterone acetate; Pfizer, New York City, New York, USA) and, perhaps, low-

113 The Tecnis Z9000 IOL (Pfizer, New York) has been designed with a modified prol

114 The Tecnis Z9000 intraocular lens (IOL) (Pfizer, New York) is the first foldable IOL designed to

115 eated with the p38 MAPK inhibitor PHA666859 (Pfizer, New York, NY) and untreated-and compared with ag

116 mercial preparation of latanoprost (Xalatan; Pfizer, New York, NY) in monkey eyes with laser-induced

117 ataracts in participants not taking Centrum (Pfizer, New York, NY) multivitamins.

118 Sildenafil (Viagra; Pfizer, New York, NY), a selective phosphodiesterase typ

119 Cancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Counc

120 Pfizer's branded lantanoprost, Xalatan (New York, New Yo

121 An X-ray-based fragment screen of Pfizer's proprietary fragment collection has resulted in

122 tor, candoxatrilat (8 and 80 microg/kg/min) (Pfizer, Sandwich United Kingdom).

123 as tested by using an antagonist, CJ-12,255 (Pfizer), that blocks the binding of SP to the neurokinin

124 e used the small molecule compound CP-31398 (Pfizer) to restore wild-type p53 function to the codon 2

125 ondon School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bil

126 Pfizer, UK National Institute for Health Research Biomed

127 edicinal agent pregabalin (commercialized by Pfizer under the trade name Lyrica) is also presented.

128 trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level long

129 ntaining ACC inhibitors recently reported by Pfizer were metabolized in vivo by ketone reduction, whi

130 rabbits (n=8; candoxatril, 30 mg/kg per day, Pfizer) were euthanized after 8 weeks of feeding.